Table 1 Baseline Characteristics of Participants.
Baseline Characteristics | 7/8 ABA | 8/8 control | p value |
|---|---|---|---|
(N = 27) | (N = 65) | ||
Age at transplant, years | 0.65 | ||
Median (range) | 12 (1–22) | 11 (<1–24) | |
Age at transplant, grouped, no. (%) | 0.16 | ||
0–9 years | 13 (48) | 26 (40) | |
10–19 years | 11 (41) | 37 (57) | |
20–24 years | 3 (11) | 2 (3) | |
Sex, no. (%) | 0.07 | ||
Male | 18 (67) | 29 (45) | |
Female | 9 (33) | 36 (55) | |
Race, no. (%) | 0.01 | ||
White | 13 (48) | 47 (72) | |
Black/African American | 12 (44) | 10 (15) | |
Asian | 2 (7) | 3 (5) | |
Unknown | 0 | 5 (8) | |
Ethnicity, no. (%) | 0.68 | ||
Hispanic or Latino | 7 (26) | 11 (17) | |
Not Hispanic or Latino | 19 (70) | 51 (78) | |
Unknown | 1 (4) | 3 (5) | |
Primary disease for transplant, no. (%) | 0.05 | ||
AML | 13 (48) | 20 (31) | |
ALL | 7 (26) | 34 (52) | |
CML | 3 (11) | 1 (2) | |
MDS | 3 (11) | 6 (9) | |
Other | 1 (4) | 4 (6) | |
Disease stage, no. (%) | 0.0002 | ||
Early | 19 (70) | 18 (28) | |
Intermediate | 6 (22) | 43 (66) | |
Advanced | 2 (7) | 3 (5) | |
Not categorized | 0 | 1 (2) | |
Conditioning regimen, no. (%) | 0.11 | ||
Busulfan/Fludarabine | 9 (33) | 11 (17) | |
Busulfan/Cyclophosphamide | 7 (26) | 13 (20) | |
Total Body Irradiation/Cyclophosphamide | 7 (26) | 35 (54) | |
Fludarabine/Melphalan | 2 (7) | 3 (5) | |
Clofarabine/Busulfan/Fludarabine | 2 (7) | 3 (5) | |
Conditioning intensity, no. (%) | 0.63 | ||
Myeloablative | 25 (93) | 62 (95) | |
Reduced Intensity | 2 (7) | 3 (5) | |
Graft type, no. (%) | 0.63 | ||
Bone marrow | 25 (93) | 62 (95) | |
Peripheral blood | 2 (7) | 3 (5) | |
Median follow-up of survivors, months | 0.87 | ||
Median (range) | 24 (6–66) | 25 (7–69) |
